01—Abstract
Summary
Summary of the 8-K filed March 30, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed a Current Report on Form 8-K on March 30, 2026, furnishing a press release announcing the submission of its New Drug Application (NDA) to the FDA for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
The company states that FORTIFY, the Phase 3 trial of BBP-418, met all pre-specified primary and secondary endpoints of its 12-month interim analysis, with additional positive results on rapid and consistent treatment effect and favorable safety profile presented at the 2026 MDA Clinical and Scientific Conference. BridgeBio anticipates approval and a U.S. launch in late 2026/early 2027, based on ongoing discussions with the FDA. If approved, BBP-418 would be the first and only approved therapy for individuals with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD.
The company is also engaging regulatory agencies to identify an expedited path to approval in Europe, where BBP-418 holds Orphan Drug Designation from the EMA. The NDA may be eligible for Priority Review given Fast Track designation, and if approved, BridgeBio may qualify for a Priority Review Voucher under the Rare Pediatric Disease designation. The company also intends to initiate clinical studies in LGMD2I/R9 for individuals under 12 years of age and in LGMD2M/2U in the near future.
02—Key points
Key Highlights
- NDA for oral BBP-418 submitted to the FDA for LGMD2I/R9, a severe, progressive neuromuscular disease
- FORTIFY Phase 3 trial met all pre-specified primary and secondary endpoints at the 12-month interim analysis
- BridgeBio anticipates FDA approval and a U.S. launch in late 2026/early 2027
- BBP-418 holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, plus Orphan Drug Designation from the EMA
- Potential Priority Review eligibility and a possible Priority Review Voucher if approved
- Potential to be the first and only approved therapy for LGMD2I/R9 and possibly the first approved treatment for any form of LGMD
- Plans to pursue an expedited European approval path and start clinical studies in younger patients and in LGMD2M/2U
03—Questions
Frequently Asked Questions
What did BridgeBio announce in this 8-K filing?
BridgeBio announced the submission of a New Drug Application to the FDA for oral BBP-418 for the treatment of individuals living with LGMD2I/R9, as disclosed in a press release attached as Exhibit 99.1.
What were the results of the FORTIFY trial?
The company states that FORTIFY met all pre-specified primary and secondary endpoints of its 12-month interim analysis. The filing describes the results as statistically significant and clinically meaningful improvements in ambulation and pulmonary function, with a rapid, consistent treatment effect and favorable safety profile.
When does BridgeBio expect to launch BBP-418 in the U.S.?
BridgeBio anticipates a U.S. launch following FDA approval in late 2026/early 2027, based on ongoing discussions with the FDA.
Could BBP-418 receive expedited review or a priority voucher?
The NDA may be eligible for Priority Review due to Fast Track designation and the potential to address unmet need. Because BBP-418 holds Rare Pediatric Disease Designation, BridgeBio may qualify for a Priority Review Voucher if the drug is approved.
What are BridgeBio's plans beyond the U.S. filing?
The company is engaging regulatory agencies to identify an expedited path to approval in Europe and intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals under 12 years of age and in LGMD2M/2U in the near future.
04—Continue